# Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Source: https://onco.cc/trials/nct01874353/  
OnCo record `nct01874353` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Olaparib in ovarian cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy is a phase 3 interventional study registered as NCT01874353 by AstraZeneca, with 327 participants enrolled, started 2013-09-03 and due to reach its primary completion in 2016-09-19. Interventions recorded: Olaparib 300mg tablets and Placebo to match olaparib 300mg. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01874353
- Phase: 3
- Setting: Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
- Sponsor: AstraZeneca
- Enrolled: 327
- Outcomes: Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1): Olaparib 300mg Tablets (Global Cohort) 19.1 months vs Placebo Tablets (Global Cohort) 5.5 months vs Olaparib 300mg Tablets (China Cohort) 13.8 months vs Placebo Tablets (China Cohort) 5.5 months

## Sources

- ClinicalTrials.gov NCT01874353: https://clinicaltrials.gov/study/NCT01874353

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-sensitive ovarian cancer](https://onco.cc/cancers/platinum-sensitive-ovarian-cancer/)
- technologies: [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct01874353.json